All News
Treatment strategies for steroid free management of #relapsingpolychondritis
56 patients from a single center
#POS0149 #EULAR2025 @RheumNow https://t.co/d4I56opS02
Bella Mehta bella_mehta ( View Tweet)
Multimodal data using clinical histological and serological predictors in renal function in #sle nephritis. Using the AMP SLE data.
Low baseline eGFR and histological damage predicted worsening renal function but not NIH activity index
#POS0173 #EULAR2025 @RheumNow @andreafa https://t.co/Eh8dZXHRVX
Links:
Bella Mehta bella_mehta ( View Tweet)
#D2T #RA ~20%
#Polyrefractory 3%
Many reasons for d/c ing #Rx - D2T
AEs
Intolerance
Chronic pain
Etc
My approach is different depending on reasons why drugs were d/c
Ie ?obj inflammation vs pain or intolerance
@RheumNow @eular_org #EULAR2025
#whatmakes D2T RA difficult https://t.co/AL6TMVJIk9
Janet Pope Janetbirdope ( View Tweet)
Would you use #CAR-T in #polyrefractory #RA
#EULAR2025 @RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)
POS0150: From 12 RA registries, JAKi starts fell by ~13% after FDA safety alerts.
Tofa & bari took biggest hits; upa growth slowed but offset losses.
Real-world prescribing adapts—but doesn’t abandon.
@RheumNow #EULAR2025 https://t.co/QZ5haW2vhX
Jiha Lee JihaRheum ( View Tweet)
?fishing for + results #EULAR2025
⚠️opinion
be aware that results do not live or die on P values
Impt findings beyond primary endpoints may be Impt beyond P<0.05
Conversely
Unexpected P values in a database
❎interpret w caution
Consider as hypothesis only
@RheumNow
Janet Pope Janetbirdope ( View Tweet)
Ultrasound for ILD detection in RA 🫁
Sens 88.6
Spe 92.8
NPV 91.4
PPV 90.7
While if abnormal or high suspicion, HRCT should be the reference, I see this as an interesting tool in clinics for quick screening
POS0180 #EULAR2025 @RheumNow https://t.co/pUy0ki7Y6S
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
#HOT topic
Lung 🫁 #ultrasound for #RA #ILD
#LUS B lines vs HRCT
Single site 🇫🇷 study
V sensitive & specific
🤔needs standardization & comparison in other groups
Abst#POS-180
#EULAR2025 @RheumNow @eular_org https://t.co/PwGE4rgk40
Janet Pope Janetbirdope ( View Tweet)
Software enhances treat to target outcomes for #RA GoTreatIT
P0S0750 ##EULAR2025 @RheumNow https://t.co/GpihWr5KLA
Links:
Bella Mehta bella_mehta ( View Tweet)
Does having a synovitis in a specific joint predicts Rx damage in that same joint?
Yes
Can US synovitis predict Rx progression better than clinical synovitis at the joint level?
Not really
At 1 year, only US synovitis is, both B-mode and Doppler ass w/ Rx prog, in particular https://t.co/Wu6dDqIUYn
Aurelie Najm AurelieRheumo ( View Tweet)
Fascinating to see JAKi uptake in European JAK-pot centres
- tofa was already on the decline pre-ORAL Surveillance
- JAKi use (driven by upadacitinib) continues to grow, although maybe it’s slowed
Hopefully rational JAKi has its place #EULAR2025 POS0150 @RheumNow https://t.co/XRyHJVw821
David Liew drdavidliew ( View Tweet)
Tenosynovitis of 5th compartment independently associated w/ D2T RA in a cohort of 90+ pts compared to established RA
Erosions, Tenosynovitis and Synovitis non associated with D2T phenotype
It’d be interesting to see if this could predict D2T evolution in early RA pts
POS0185 https://t.co/faruOr3HhJ
Aurelie Najm AurelieRheumo ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its faculty
Dr. John Cush RheumNow ( View Tweet)
In #SLE, #HCQ levels >1150 ng/ml ↑toxicity risk w/o added benefit. Levels 750-1150 ng/ml linked to ↓disease activity.
CKD stage ≥3 doubled HCQ levels at same dose.
Supports monitoring & dose adjustment in CKD to balance safety & efficacy.
@RheumNow #EULAR2025 #OP0199
Mrinalini Dey DrMiniDey ( View Tweet)
OP0176: Among D2T PsA pts, 43% lacked inflammation on imaging—despite symptoms.
Clinical + US split them into PIPsA vs NIPsA, helping distinguish who needs escalation vs who doesn’t.
A step toward smarter care in D2T PsA.
@RheumNow #EULAR2025 https://t.co/E9igwvDPPN
Jiha Lee JihaRheum ( View Tweet)
New dual-action RA drug?
OP0193: CPL’116 targets both JAK & ROCK.
In 12-wk RCT, highest dose improved DAS28-CRP, joint counts & pain, with clean labs.
Is this a future option for RA-ILD or patients with comorbid CVD risk?
#EULAR2025 @RheumNow
Jiha Lee JihaRheum ( View Tweet)
PHOENYCS GO🏃: Dapirolizumab pegol (DZP) led to higher rates of LLDAS (41% vs 20%) & DORIS remission (19% vs 8%) at wk48 vs PBO+SOC. DZP showed earlier & more sustained disease control, advancing T2T in SLE.
@RheumNow #EULAR2025 #OP0201 https://t.co/zuxBELxTDd
Mrinalini Dey DrMiniDey ( View Tweet)
FAPI-PET/CT - detecting synovial and enthesial fibroblast activation- predicts the development of #psoriatic_arthritis in patients with psoriasis and arthralgia
✨️ A promising tool for early diagnosis of PsA
Giulia Corte et al.
OP#0174
#EULAR2025
@RheumNow https://t.co/QVmoECIhBI
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Ph 2 RCT CPL'116 dual inhibition JAK/ROCK
106 MTX IR pts
wk12 primary endpoint met (DAS28-CRP decrease) in 240mg arm vs. PBO
75% >= AEs, SAE 2: 1 MI, 1 bladder cancer
Authors suggest absence of lipids/LFTs disruption compared to other JAKs
Ph3 is awaited!!
#OP0193 #EULAR2025 https://t.co/TnnM410LfM
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
✨️ New Definition Alert
The GRAPPA definition of
C2M (Complex to Manage)
&
D2T (Difficult to Treat)
#Psoriatic_arthritis
A hope for having a homogeneous and widely accepted definition for future clinical research
Presented at #EULAR2025
Proft et al.
OP#0175
@RheumNow https://t.co/et9cuMROkb
Nelly ZIADE 🍀 Nellziade ( View Tweet)
